First patient dosed in phase II study of OTX-DED for short-term treatment of dry eye disease March 2, 2021 No Comments
Oxular advancing once-per-year DME treatment with $37M series B March 1, 2021 By Nuala Moran No Comments LONDON – Oxular Ltd. has raised $37 million in a series B, enabling the company to take OXU-001, its long-acting treatment for diabetic macular edema (DME) into phase II development later this year.Read More
Last patient completes final visit for NORSE THREE safety study of ONS-5010 Feb. 12, 2021 No Comments
RSS
